ABOzymes Biomedical Revenue and Competitors

ABOzymes Biomedical Inc. (“ABOzymes”) is an early-stage enterprise with an innovative, unique, and proprietary platform that enables a world where a person’s blood type is no longer the first constraint when patients need life-saving organ transplants or blood transfusions. ABOzymes’ first product, ABOperfusion-A, is an additive to existing organ preservation solutions. The enzymes prime and then eliminate the marker on cells that determines blood group A rendering it group O, the universal donor type. By converting group A organs for transplantation to group O organs, our technology will enable more organ matching opportunities, optimize allocation, ensure more equitable distribution of donor organs and ultimately reduce the waiting list times of patients waiting for a life saving transplant procedure.